DC 806
Alternative Names: DC-806; LY-4100504; S-011806Latest Information Update: 19 Jul 2024
At a glance
- Originator DiCE Molecules
- Developer DICE Therapeutics
- Class Antipsoriatics; Small molecules
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Plaque psoriasis
- Phase I Immunological disorders; Psoriasis
Most Recent Events
- 26 Mar 2024 DICE Therapeutics completes a phase II trial in Plaque psoriasis in USA (PO) (NCT05896527)
- 28 Nov 2023 DICE Therapeutics completes a phase I drug-drug interaction trial(In volunteers) in USA (PO) (NCT06092931)
- 16 Oct 2023 DICE Therapeutics initiates a phase I drug-drug interaction trial (In volunteers) in USA (PO) (NCT06092931)